玻璃体腔内注射雷珠单抗治疗视网膜静脉阻塞合并黄斑水肿的效果与安全性

Effect and safety of intravitreal injection of lucentis in the treatment of retinal vein occlusion combined with macular edema

目的分析玻璃体腔内注射雷珠单抗治疗视网膜静脉阻塞(RVO)合并黄斑水肿的效果与安全性。方法选取2019年1月至2021年8月我院收治的50例RVO合并黄斑水肿患者作为研究对象,根据玻璃体腔内注射药物不同将其分为常规组(25例,曲安奈德)和观察组(25例,雷珠单抗)。比较两组不同时间点的裸眼视力(UCVA)、最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度及治疗期间的不良事件发生情况。结果T_(0)~T_(2)时,两组的UCVA、BCVA、黄斑中心凹视网膜厚度比较,差异无统计学意义(P>0.05);T_(3)~T_(4)时,观察组的UCVA、BCVA高于常规组,黄斑中心凹视网膜厚度小于常规组,差异具有统计学意义(P<0.05)。治疗期间,观察组的不良事件总发生率为4.00%,低于常规组的24.00%,差异具有统计学意义(P<0.05)。结论玻璃体腔内注射雷珠单抗治疗RVO合并黄斑水肿可改善视力及黄斑中心凹视网膜厚度,且安全性较高,值得临床推广和应用。

Objective To analyze the effect and safety of intravitreal injection of lucentis in the treatment of retinal vein occlusion(RVO)combined with macular edema.Methods A total of 50 patients with RVO combined with macular edema treated in our hospital from January 2019 to August 2021 were selected as the research objects.According to the different intravitreal injection drugs,the patients were divided into routine group(25 cases,triamcinolone acetonide)and observation group(25 cases,lucentis).The uncorrected visual acuity(UCVA),best corrected visual acuity(BCVA),macular foveal retinal thickness at different time points and occurrence of adverse events during treatment were compared between the two groups.Results At T_(0)-T_(2),there were no significant differences in UCVA,BCVA and macular foveal retinal thickness between the two groups(P>0.05);at T_(3)-T_(4),the UCVA and BCVA in the observation group were higher than those in the routine group,the macular foveal retinal thickness was less than that in the routine group,and the differences were statistically significant(P<0.05).During treatment,the total incidence of adverse events in the observation group was 4.00%,which was lower than 24.00% in the routine group,and the difference was statistically significant(P<0.05).Conclusion Intravitreal injection of lucentis in the treatment of RVO combined with macular edema can improve visual acuity and macular foveal retinal thickness,with high safety,which is worthy of clinical promotion and application.